Dai Wei-xin, Lian Xiao-lan, Lu Lin, Li Su-mei, Li Shu-hua, Li Xiu-wei
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Zhonghua Yi Xue Za Zhi. 2003 Dec 25;83(24):2142-5.
To investigate the effect of universal salt iodization (USI) on antithyroid drug.
One hundred and one patients with untreated hyperthyroidism were randomly divided into two sex and age-matched groups: group A (n = 45, consuming pure salt without iodine) and group B (n = 56, consuming iodated salt). The same dosage of 300 mg propylthiouracil (PTU) was given to both groups at beginning, the serum TT4. TT3, FT4, FT3, and TSH were measured before and 1, 2, 3, 6 months after PTU treatment, when the serum TT4, TT3, FT4. FT3, and TSH were back to the normal ranges, the dosage of PTU was decreased to maintain the normal levels of serum thyroid hormones.
The urine iodine and serum thyroid hormone levels were not significantly different between group A and group B before the treatment (P > 0.05). The urine iodine of group A was significant lower 2 - 3 months after the treatment (148.4 micro g/L) than before the treatment (213.4 micro g/L, P < 0.01). There were not significant differences in serum TT4, TT3, FT4, and FT3 between group A and B before the treatment (all P > 0.05). One month after the treatment the serum TT4 and TT3 in group A were (153 +/- 50) nmol/L and (3.6 +/- 1.2) nmol/L respectively, both significantly lower than those of the group B [(177 +/- 64) nmol/L and (2.7 +/- 1.5) nmol/L respectively, P = 0.041 and 0.033], however, there was no significant difference in other serum thyroid hormones between the group A and group B. The dosage of PTU was not significantly different between group A and B 1 month after the treatment, but became significantly higher in group B than in group A 2, 3, and 6 months after the treatment (214,189, and 178 mg/d respectively vs. 190, 147, and 116 mg/d respectively, and 24, 42, and 62 mg/day more respectively, all P < 0.05).
Hyperthyroidism can be effectively controlled by PTU while the patients consume iodated salt, but the dosage of PUT needed should be higher than while the patients consume pure salt.
探讨全民食盐加碘（USI）对抗甲状腺药物的影响。
101例未经治疗的甲状腺功能亢进患者随机分为两组，两组在性别和年龄上相匹配：A组（n = 45，食用无碘纯盐）和B组（n = 56，食用加碘盐）。两组开始时均给予相同剂量300mg丙硫氧嘧啶（PTU），在PTU治疗前及治疗后1、2、3、6个月测定血清TT4、TT3、FT4、FT3和TSH，当血清TT4、TT3、FT4、FT3和TSH恢复至正常范围时，减少PTU剂量以维持血清甲状腺激素水平正常。
治疗前A组和B组尿碘及血清甲状腺激素水平差异无统计学意义（P > 0.05）。治疗后2 - 3个月A组尿碘（148.4μg/L）显著低于治疗前（213.4μg/L，P < 0.01）。治疗前A组和B组血清TT4、TT3、FT4和FT3差异无统计学意义（均P > 0.05）。治疗1个月后A组血清TT4和TT3分别为（153±50）nmol/L和（3.6±1.2）nmol/L，均显著低于B组[分别为（177±64）nmol/L和（2.7±1.5）nmol/L，P = 0.041和0.033]，然而，A组和B组其他血清甲状腺激素差异无统计学意义。治疗1个月后A组和B组PTU剂量差异无统计学意义，但治疗2、3和6个月后B组PTU剂量显著高于A组（分别为214、189和178mg/d，而A组分别为190、147和116mg/d，分别多24、42和62mg/d，均P < 0.05）。
甲状腺功能亢进患者食用加碘盐时，PTU可有效控制病情，但所需PTU剂量高于食用无碘纯盐时。
